Crystal Research Associates has issued a 15-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).
Snapshot of GeoVax
GeoVax Labs, Inc. (“GeoVax” or “the Company”) is a clinical-stage biotechnology company developing preventive and therapeutic human vaccines and immunotherapies against infectious diseases and cancer. The Company’s proprietary GV-MVA-VLP™ vector vaccine technology utilizes a Modified Vaccinia Ankara (MVA) vector, a large virus capable of carrying several vaccine antigens, that are expressed as non-infectious virus-like particles (VLPs) in the individual receiving the vaccine (in vivo). VLPs mimic a natural infection, stimulating both the humoral (antibody) and cellular (T-cells) arms of the immune system to recognize, prevent, and control the target infection through durable immune responses.
GeoVax is capitalizing on the safety and efficacy of its technology platform to address the need for a broadly-effective COVID-19 vaccine and is also developing vaccines against human immunodeficiency virus (HIV), Zika virus (ZIKV), hemorrhagic fever (HF) viruses (Ebola, Sudan, Marburg, and Lassa Fever), and malaria. Furthermore, the Company is applying its MVA-VLP technology to cancer immunotherapy (immuno-oncology).
Key Points of GeoVax's Business
- On August 11, 2021, GeoVax reported second quarter 2021 financial results and provided a Company update. For the three months ended June 30, 2021, GeoVax reported a net loss of $1,314,033 ($0.21 per share) versus a net loss of $455,204 ($0.66 per share) for the same period in 2020. For the six months ended June 30, 2021, the Company reported a net loss of $2,876,811 ($0.49 per share) versus a net loss of $1,050,898 ($2.27 per share) in 2020.
- Regarding the Company’s COVID-19 vaccine efforts, GeoVax’s vaccine is based on its proprietary GV-MVA-VLPTM technology, enabling insertion of multiple antigen fragments and potentially allowing for broad-spectrum virus prevention. Unique from other vaccines that target only the COVID-19 spike protein, GeoVax’s vaccines are designed to provoke a response to multiple COVID-19 antigens, which could translate into it being less susceptible to viral mutations. The Company’s vaccines are intended to be used as either a primary vaccine or a booster to other COVID-19 vaccines as part of vaccination strategies to provide immunity to a range of coronavirus variants.
- Small animal studies are continuing with results, to date, supporting GeoVax’s approach of using MVA as a vector for the design and production of “next-generation” COVID-19 vaccines encoding multiple proteins. Details of these studies will be presented on August 19, 2021 during the European Society of Medicine (ESMED) General Assembly.
- In addition to COVID-19, the Company expects several data announcements from its development programs in the coming weeks and months, particularly within the areas Lassa Fever virus, Sudan/Marburg virus, and immuno-oncology.
- GeoVax continues to strengthen its intellectual property portfolio, with over 70 granted or pending patent applications across 20 patent families. In February 2021, the Company filed international and U.S. patent applications in its key focus areas of SARS-CoV-2 (COVID-19) and cancer immunotherapy, and in July 2021, announced the issuance of a U.S. patent covering its Hepatitis B vaccine.
- As of June 30, 2021, GeoVax’s reported cash balance was $19.5 million versus $9.9 million at December 31, 2020. Adding to the increase in cash balances were net proceeds of $9.4 million from the sale of 1,644,000 shares of common stock, and $3.2 million from the exercise of warrants to purchase 690,034 shares of common stock.
for the latest research on GeoVax Labs, Inc.